Last reviewed · How we verify
Event-driven dosing
At a glance
| Generic name | Event-driven dosing |
|---|---|
| Also known as | A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate. |
| Sponsor | HIV Prevention Trials Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. (PHASE3)
- The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP) (PHASE2)
- Biomarkers for Event-driven PrEP Adherence (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Event-driven dosing CI brief — competitive landscape report
- Event-driven dosing updates RSS · CI watch RSS
- HIV Prevention Trials Network portfolio CI